This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 2002;287:2203.

	Since this article does not have an abstract, we have provided the first 101 words of the full text and any section headings.

The FDA and the Plasma Protein Therapeutics Association (PPTA) will conduct on May 30-31 a public workshop entitled "Comparability Studies for Human Plasma-Derived Therapeutics." The workshop, to be held at the Doubletree Executive Meeting Center, 1750 Rockville Pike, Rockville, Md, will discuss among other issues the FDA perspective on the design of clinical studies to evaluate comparability of plasma-derived therapeutics. The goal is to provide sponsors with information that will increase their ability to bring such products to market. For registration and additional information, log on to http://www.fda.gov/cber/whatsnew.htm.

AUTHOR INFORMATION

Written inquiries may be directed to Office of the Commissioner of Food and Drugs, HF-1, Room 14-71, 5600 Fishers Ln, Rockville, MD 20857.

Lester M. Crawford, Jr, DVM,PhD
Deputy Commissioner
US Food and Drug Administration